JP2022551198A5 - - Google Patents

Info

Publication number
JP2022551198A5
JP2022551198A5 JP2022546590A JP2022546590A JP2022551198A5 JP 2022551198 A5 JP2022551198 A5 JP 2022551198A5 JP 2022546590 A JP2022546590 A JP 2022546590A JP 2022546590 A JP2022546590 A JP 2022546590A JP 2022551198 A5 JP2022551198 A5 JP 2022551198A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
pharmaceutically acceptable
occurrence
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022546590A
Other languages
English (en)
Japanese (ja)
Other versions
JP7822940B2 (ja
JP2022551198A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054360 external-priority patent/WO2021071812A1/en
Publication of JP2022551198A publication Critical patent/JP2022551198A/ja
Publication of JP2022551198A5 publication Critical patent/JP2022551198A5/ja
Application granted granted Critical
Publication of JP7822940B2 publication Critical patent/JP7822940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022546590A 2019-10-07 2020-10-06 Kv1.3カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物 Active JP7822940B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911652P 2019-10-07 2019-10-07
US62/911,652 2019-10-07
PCT/US2020/054360 WO2021071812A1 (en) 2019-10-07 2020-10-06 Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers

Publications (3)

Publication Number Publication Date
JP2022551198A JP2022551198A (ja) 2022-12-07
JP2022551198A5 true JP2022551198A5 (cg-RX-API-DMAC7.html) 2024-05-15
JP7822940B2 JP7822940B2 (ja) 2026-03-03

Family

ID=75436856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546590A Active JP7822940B2 (ja) 2019-10-07 2020-10-06 Kv1.3カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物

Country Status (11)

Country Link
US (1) US20220411367A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041228A4 (cg-RX-API-DMAC7.html)
JP (1) JP7822940B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079881A (cg-RX-API-DMAC7.html)
CN (1) CN114727993B (cg-RX-API-DMAC7.html)
AU (1) AU2020363360A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006226A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157031A1 (cg-RX-API-DMAC7.html)
IL (1) IL291869A (cg-RX-API-DMAC7.html)
MX (1) MX2022004145A (cg-RX-API-DMAC7.html)
WO (1) WO2021071812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782894A (zh) 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100008794A (ko) * 2001-04-16 2010-01-26 쉐링 코포레이션 Cxc-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
US20100099674A1 (en) * 2007-03-21 2010-04-22 Innate Pharmaceuticals Ab Method and means for preventing and inhibiting type iii secretion in infections caused by gram-negative bacteria
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
JP2020502064A (ja) * 2016-11-29 2020-01-23 エピザイム,インコーポレイティド スルホン酸基を含むkat阻害剤としての化合物
CA3073669A1 (en) * 2017-08-22 2019-02-28 Cedars-Sinai Medical Center Compositions and methods for treating cancer

Similar Documents

Publication Publication Date Title
JP2022550640A5 (cg-RX-API-DMAC7.html)
JP2022551197A5 (cg-RX-API-DMAC7.html)
JP2022552445A5 (cg-RX-API-DMAC7.html)
JP2022550641A5 (cg-RX-API-DMAC7.html)
JP2023544404A5 (cg-RX-API-DMAC7.html)
JP2023539584A5 (cg-RX-API-DMAC7.html)
JP2024050527A5 (cg-RX-API-DMAC7.html)
JP4724665B2 (ja) キノリノン化合物を合成する方法
JP2024167182A5 (cg-RX-API-DMAC7.html)
JP2022541825A5 (cg-RX-API-DMAC7.html)
JP2024100974A5 (cg-RX-API-DMAC7.html)
JP2021523221A5 (cg-RX-API-DMAC7.html)
JP2013530236A5 (cg-RX-API-DMAC7.html)
KR20210049858A (ko) Jak 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리딘 화합물 및 이의 용도
EP3490987A1 (en) Novel therapeutic agents for the treatment of hbv infection
UA74066C2 (en) Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment
SG177221A1 (en) Novel oxadiazole compounds
JP2015533782A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2021502387A5 (cg-RX-API-DMAC7.html)
JP2022519239A5 (cg-RX-API-DMAC7.html)
JP2025505644A5 (cg-RX-API-DMAC7.html)
JP2023164918A5 (cg-RX-API-DMAC7.html)
JP2010526867A5 (cg-RX-API-DMAC7.html)
JP2020537671A5 (cg-RX-API-DMAC7.html)
JP2024522718A (ja) 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物